Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Poh · SciRah

Researcher profile · Semantic Scholar

C. Poh

Share profile

C. Poh — researcher profile on SciRah

h-index: 11
Works: 71
Citations: 453

Most-cited papers

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.
R. Lynch, C. Ujjani, C. Poh, E. Warren +22 more
2023Blood82 citations Open access
Semantic Scholar
Secondary Primary Malignancies in Multiple Myeloma: A Review
C. Poh, T. Keegan, A. Rosenberg
2020Blood reviews69 citations Open access
Semantic Scholar
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
C. Poh, P. Frankel, C. Ruel, M. Abedi +10 more
2019Blood28 citations Open access
Semantic Scholar
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
L. Sehn, S. Luminari, C. Scholz, K. Hübel +17 more
2024Blood22 citations
Semantic Scholar
Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
R. Banerjee, C. Poh, A. Hirayama, J. Gauthier +8 more
2024Blood Advances20 citations Open access
Semantic Scholar
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
R. Lynch, C. Poh, C. Ujjani, E. Warren +17 more
2022Blood Advances18 citations Open access
Semantic Scholar
Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study
C. Poh, J. Mcpherson, J. Tuscano, Qian Li +4 more
2022BMC Medicine16 citations Open access
Semantic Scholar
Development and validation of predictive models of early immune effector cell–associated hematotoxicity
Emily C. Liang, Jennifer J. Huang, A. Portuguese, V. Ortíz-Maldonado +29 more
2024Blood Advances15 citations
Semantic Scholar
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia
C. Poh, M. Arora, S. Ghuman, J. Tuscano
2020Acta Haematologica14 citations
Semantic Scholar
Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome
R. Lynch, C. Poh, M. Shadman, B. Till +12 more
2023Blood13 citations Open access
Semantic Scholar
Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality
C. Poh, A. Brunson, T. Keegan, T. Wun +1 more
2020TH Open12 citations Open access
Semantic Scholar
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up
A. Portuguese, Jennifer J. Huang, Yein Jeon, Mahnoosh Taheri +17 more
2025Haematologica10 citations Open access
Semantic Scholar
Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD
R. Lynch, S. Alig, C. Ujjani, C. Poh +17 more
2023Blood10 citations Open access
Semantic Scholar
The impact of B‐cell‐directed therapy on SARS‐CoV‐2 vaccine efficacy in chronic lymphocytic leukaemia
C. Ujjani, M. Shadman, R. Lynch, Brian Tu +16 more
2022British Journal of Haematology10 citations Open access
Semantic Scholar
Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
Jasmine M. Zain, S. Iyer, Enrica Marchi, M. Gandhi +12 more
2024Blood9 citations
Semantic Scholar
Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
A. Portuguese, Aya Albittar, Jennifer J. Huang, Emily C. Liang +16 more
2024Transplantation and Cellular Therapy9 citations Open access
Semantic Scholar
Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL
Laura Samples, C. Ujjani, Sirin Khajaviyan, R. Lynch +10 more
2023Blood9 citations Open access
Semantic Scholar
Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL
M. Shadman, Cecilia C. S. Yeung, M. Redman, Sang-Yun Lee +18 more
2021Blood9 citations Open access
Semantic Scholar
Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
C. Poh, V. Chow, R. Lynch, C. Ujjani +14 more
2023Blood6 citations Open access
Semantic Scholar
Upper extremity deep venous thrombosis in 10 common malignancies: Analysis of incidence, risk factors, and effect on mortality from the California Cancer Registry.
C. Poh, A. Brunson, Anjlee Mahajan, T. Keegan +1 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
Thomas M Kuczmarski, C. Ujjani, C. Poh, E. Warren +12 more
2024Blood5 citations
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
M. Shadman, C. Yeung, M. Redman, S. Y. Lee +21 more
2023Hematological Oncology5 citations Open access
Semantic Scholar
Long-term Follow-up and Correlative Analysis of two Phase 2 Trials of Rituximab and Lenalidomide followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
J. Tuscano, C. Poh, P. Kaesberg, Guillaume Luxardi +6 more
2021Clinical Cancer Research5 citations Open access
Semantic Scholar
Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
C. Poh, V. Chow, R. Lynch, C. Ujjani +14 more
2024Transplantation and Cellular Therapy3 citations Open access
Semantic Scholar
Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Carrie Ho, A. Gopal, C. Ujjani, R. Lynch +6 more
2023Blood3 citations Open access
Semantic Scholar
Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting
A. Portuguese, Aya Albittar, Emily C. Liang, Jennifer J. Huang +14 more
2023Blood3 citations Open access
Semantic Scholar
Efficacy of Short-Duration Alemtuzumab in T-Cell Large Granular Lymphocytic Leukemia: Potential for a Response-Adapted Strategy
C. Poh, A. Shustov, I. Huang, A. Gopal +1 more
2022Blood3 citations Open access
Semantic Scholar
S207: EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL)
M. Shadman, C. Yeung, M. Redman, S. Y. Lee +20 more
2022HemaSphere3 citations Open access
Semantic Scholar
High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL
M. Shadman, Cecilia C. S. Yeung, M. Redman, Sang-Yun Lee +18 more
2022Transplantation and Cellular Therapy3 citations Open access
Semantic Scholar
Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma
R. Lynch, C. Ujjani, C. Poh, E. Warren +21 more
2021Blood3 citations Open access
Semantic Scholar
Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lymphoma (LBCL) Patients
N. Wuliji, Rahul Banerjee, Emily C. Liang, Jennifer J. Huang +31 more
2024Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
Grace T. Baek, Gaurav Varma, S. Yamshon, H. V. van Besien +24 more
2024Blood2 citations
Semantic Scholar
Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors
Laura Samples, Sirin Khajaviyan, R. Lynch, Mehrdad Shakib-Azar +11 more
2023Blood2 citations Open access
Semantic Scholar
Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification
Carrie Ho, David Wu, Q. Wu, K. Ng +9 more
2023Blood2 citations Open access
Semantic Scholar
Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin
C. Poh, R. Lynch, E. Warren, C. Ujjani +9 more
2023Blood2 citations Open access
Semantic Scholar
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma
Lorena Panaite, Q. Wu, J. Voutsinas, Erin Mullane +12 more
2022Leukemia and Lymphoma2 citations
Semantic Scholar
Evaluation of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies: Lessons learned from a 14‐year retrospective study
Jason Tau, Leonor P. Fernando, Meilen C Muñoz, C. Poh +2 more
2022Therapeutic apheresis and dialysis2 citations
Semantic Scholar
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
J. Tuscano, C. Poh, A. Rosenberg, B. Jonas +5 more
2020Journal of Hematology2 citations Open access
Semantic Scholar
Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center
C. Poh, E. Al-Obeidi, J. Tuscano, A. Rosenberg +2 more
20202 citations Open access
Semantic Scholar
Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)
S. Iyer, LaQuisa C. Hill, S. Horwitz, Salvia Jain +7 more
2024Blood1 citations
Semantic Scholar
Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
Emily C. Liang, Aya Albittar, A. Portuguese, Jennifer J. Huang +26 more
2024Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
Aya Albittar, J. Voutsinas, A. Portuguese, Jennifer J. Huang +16 more
2024Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
Ryan C. Lynch, S. Alig, C. Ujjani, C. Poh +16 more
2024Blood1 citations
Semantic Scholar
Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie +13 more
2024Blood1 citations
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
R. Lynch, C. Poh, M. Shadman, B. Till +11 more
2023Hematological Oncology1 citations Open access
Semantic Scholar
Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
Aya Albittar, J. Voutsinas, A. Portuguese, Jennifer J. Huang +15 more
2023Blood1 citations
Semantic Scholar
Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas
C. Poh, Xinyi Fan, J. Voutsinas, Q. Wu +9 more
2023Blood1 citations Open access
Semantic Scholar
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma
Maryam Ebadi, Xinyi Fan, G. Schoch, T. Gooley +17 more
2023Blood1 citations Open access
Semantic Scholar
Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
Ilaria Romano, J. Gauthier, R. Lynch, A. Gopal +12 more
2023Blood1 citations Open access
Semantic Scholar
Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy
Emily C. Liang, Aya Albittar, A. Portuguese, Jennifer J. Huang +24 more
2023Blood1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Till×26
Invite
B. Till — researcher profile on SciRah
C. Ujjani×25
Invite
C. Ujjani — researcher profile on SciRah
A. Gopal×25
Invite
A. Gopal — researcher profile on SciRah
R. Lynch×23
Invite
R. Lynch — researcher profile on SciRah

×17

Invite

J. Voutsinas — researcher profile on SciRah

Invite

M. Shadman — researcher profile on SciRah

J. Gauthier×16

Invite

J. Gauthier — researcher profile on SciRah

Invite

D. Maloney — researcher profile on SciRah

Stephen D. Smith×15

Invite

Stephen D. Smith — researcher profile on SciRah

Invite

A. Chapuis — researcher profile on SciRah

Invite

M. Shadman — researcher profile on SciRah

Invite

E. Warren — researcher profile on SciRah